Rigel Pharmaceuticals (RIGL) stock

Market cap $877M

$47.15

+0.38%

Market closed. Prices as of today's close.

Quality Score

Above Average

In its industry

#17of 300

Biotech

Checks firing

4of 14

Trending up

From 52-week high

-9.7%

Above the 200-day

NextEnd of 2026“…study, select a recommended Phase 2 dose in the second half of 2026 and share preliminary data by year end…”Trial data · 8-K, Aug 4

Follow RIGL's trial news. Pro members can get an alert when Rigel Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.

Get an optional alert when RIGL files news on its trialsFree for 24 hours. No account needed.

Pipeline

What's next for RIGL

From Rigel Pharmaceuticals’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.

Next step the company has named

End of 2026“…and remain on track to complete enrollment in the dose expansion phase of the study, select a recommended Phase 2 dose in the second half of 2026 and share preliminary data by year end.”Trial data · 8-K, Aug 4

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway: Olutasidenib and Temozolomide in HGGPhase 2 · Recruiting · 60 people · main data estimated Jun 2029 · NCT06161974

4 more trials, 1 more milestone and 34 filings, for Pro members.

Dilution on the horizon

No shelf registration of its own or at-the-market program on file in the last three years.

A shelf lets a company sell shares later; an at-the-market program sells them into the market over time. Neither is a sale by itself.

For Pro members: the amounts, and the share count against a year ago.

Insiders

Director Kamil Ali-Jackson sold 2,500 shares on Jun 22, under a planned sale. 2 more insider trades this year.

From their own Form 4 filings: buys and sales in the market, not awards or shares withheld for tax.

Get an optional alert when Raul Rodriguez buys or sells

For Pro members: every trade, and Raul Rodriguez’s 17 filings and quotes.

Get an optional alert when RIGL files news on its trialsFree for 24 hours. No account needed.

See every upcoming FDA date →

Biotech dates

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.

DateStockDrug

In 28 daysFDA decisionIn 28 days · FDA decisionINOInovio PharmaceuticalsINO-3107INOInovio Pharmaceuticals · $125MINO-3107Under FDA review
In 39 daysANDA decisionIn 39 days · ANDA decisionNRXPNRX PharmaceuticalsDrug not namedNRXPNRX Pharmaceuticals · $123MDrug not namedA generic, under FDA review
In 51 daysFDA decisionIn 51 days · FDA decisionCAPRCapricor TherapeuticsDrug not namedCAPRCapricor Therapeutics · $520MDrug not namedUnder FDA review

8 more FDA dates and 114 trial data dates in the next 60 days. Pro members see every one, with the cash against its date and an optional alert before it. Get in free →

Quality Score

Why RIGL scores 13

Above AverageTrending up, 4 of 14 checks firingWhat the Quality Score means

Poor is below 0. Average starts at 6, Above Average at 11, Excellent at 15, and Exceptional at 20.

+4Chart checks 4 of 14 firing right now, one point each
+3Long-term trend above a rising 200-⁠day average, near its 52-⁠week high

Run-up adds
Profit addsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Persistence adds

No effect today: Size, Growth, Dilution, Volatility, Cash flow, and News.

What every line is worth, and the reason behind it, on RIGL and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:46 PM ET, at least 15 minutes behind. How we rank stocks.

What's next

Mon Oct 5: World Clinical Biomarkers (CB)…Industry event · date confirmed.

Expected to report Tue Nov 3, after the close

After its last 4 reports it closed +5.7% on average, higher 2 of 4 times.

What would move RIGL's score: 3 things, for Pro members

Alert me when RIGL's Quality Score turns up

Free for 24 hours. No account needed. Then keep going with a free account.

Pro

Here is what Pro members see.

Every stock has a live page like this, RIGL included: the price in real time, the full chart, all 14 checks, and every line of its score.

AMD's page for Pro members on a phone, recorded live: the price changes as it trades, beside its Quality Score and its rank, with the bid and ask under it and a year of candles below — The same page for Pro members, on AMDThe live price and the full chart, with the Quality Score drawn under it and the line that drives it.

A Pro member's stock page for AMD: its Quality Score with its rank and the line driving it, the live price with the bid and ask, the chart checks, strength, and next earnings, and a year of candles with the 21 and 50-day averages and the Quality Score drawn under the chart — The same page for Pro members, on AMDThe live price and the full chart, with the Quality Score drawn under it and the line that drives it.

The Score tab on a phone: how AMD's Quality Score adds up from price action, the company, and signals, its rank, and the chart checks by group, trend, volume, tight range, and buying — Every line of the scoreWhat each part adds, and all 14 checks by group, on RIGL and every other stock.

The New alert form on a phone: watch one name, AMD, when its Quality Score is at least 20, sent by the bell on the site, a push notification, and email, with the Save alert button — Your own optional alertsPick what to watch, RIGL or your whole watchlist, and when: a Quality Score, a price, a filing. It comes by push, email, or the bell.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

The 14 checks

RIGL has 4 of 14 checks firing

One per group is shown here.

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Averages stacked in order, price near its high.

Volume1 of 3 shown

VOL VDU U/D VOL

Heavy volume on the run, quiet volume at rest.

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

The daily range is tight against its own recent history.

Buying1 of 3 shown

OBV+CLOSE HI SPRING

Closes near the high, and buyers step in on dips.

The other 10 checks on RIGL, and all 14 on every stock.Get in free →

Also on the chart

Not scored

Shown for reference. None of these counts toward the Quality Score: in our tests on 20 years of daily prices, none of them improved it.

RSI 1452.3
Above 50, below 70.
MACD (12, 26, 9)Below signal
Crossed below its signal line 2 sessions ago.
50-day average$44.48
The price is 6.0% above it.
200-day average$36.54
The price is 29.0% above it. The 50-day is above the 200-day, since Jul 23.
ADX 1424.2
Under 25, with +DI above -DI.
Support$43.78
Swing low from Sep 16, 7.1% below the price.
Resistance$49.10
Swing high from Jan 7, 4.1% above the price.
Bollinger Bands (20, 2)Inside
The bands run from $44.55 to $49.96.
Volume0.8x
Against its 20-day average, for the time of day.

Its industry

How RIGL ranks in Biotech

RIGL is #17 of 300 by Quality Score. The top three are shown with their scores, and more by name.

1KNSAKiniksa Pharmaceuticals International7/1418
2EXELExelixis7/1417
3AMRXAmneal Pharmaceuticals6/1417
RGENRepligenOpen for its score
RGNXREGENXBIOOpen for its score
RLMDRelmada TherapeuticsOpen for its score
RPRXRoyalty PharmaOpen for its score
17RIGLRigel Pharmaceuticals4/1413

When does RIGL report earnings, and what happens after?

Expected to report Tue Nov 3, after the close (in 32 days). Not yet confirmed by the company.

+33.4%-10.3%-5.1%+4.6%

Nov 4Mar 3May 5Aug 4

Reported	When	Gap	Reaction	5 sessions
Aug 4, 2026After close	After close	+9.8%	+4.6%	+8.6%
May 5, 2026After close	After close	+2.2%	-5.1%	+4.6%
Mar 3, 2026After close	After close	-8.3%	-10.3%	-13.9%
Nov 4, 2025After close	After close	+22.9%	+33.4%	+33.7%

The gap is the next open against the close before the report; the reaction is where that session closed. RIGL closed higher after 2 of its last 4. Past behavior, not a forecast.

Report dates and past reactions come from sessions that have already closed, so none of these figures move.

The company

About Rigel Pharmaceuticals

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.

174 employeesSouth San Francisco, CArigel.com

Pro

Every line of the score, on every stock.

Real-time prices, no delay
Every line of RIGL's score, with the points and the reason
All 14 checks on RIGL and on all 3,243 stocks
Every stock ranked, with the chart
Every filing, and optional alerts on RIGL

See all 14 checks on RIGLFree for 24 hours. No account needed. Then keep going with a free account.

Questions

Straight Answers.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.